Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen) Európska únia - slovenčina - EMA (European Medicines Agency)

aripiprazole mylan pharma (previously aripiprazole pharmathen)

mylan pharmaceuticals limited - aripiprazol - schizophrenia; bipolar disorder - psycholeptika - aripiprazol mylan pharma je indikovaný na liečbu schizofrénie u dospelých a u dospievajúcich vo veku 15 rokov a starších. aripiprazole mylan pharma je indikovaný na liečbu stredne závažných manických epizód v bipolárna som porucha a prevencie nový manické epizódy u dospelých, ktorí zažili prevažne manické epizódy a ktorých manické epizódy reagoval na aripiprazole liečba. aripiprazole mylan pharma je indikovaný na liečbu až 12 týždňov stredne závažných manických epizód v bipolárna som porucha u dospievajúcich vo veku 13 rokov a starších.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Európska únia - slovenčina - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrel hydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotické činidlá - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Rivastigmine 3M Health Care Ltd Európska únia - slovenčina - EMA (European Medicines Agency)

rivastigmine 3m health care ltd

3m health care limited - rivastigmín - alzheimerova choroba - psychoanaleptics, , anticholinesterases - symptomatická liečba miernej až stredne ťažkej alzheimerovej demencie.

Voriconazole Accordpharma 200 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

voriconazole accordpharma 200 mg

accord healthcare polska sp. z o.o., poľsko - vorikonazol - 26 - antimycotica (lokÁlne a celkovÉ)

Diclofenac Duo Bausch Health 75 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

diclofenac duo bausch health 75 mg

bausch health ireland limited , Írsko - diklofenak - 29 - antirheumatica, antiphlogistica, antiuratica

Meropenem Bausch Health 500 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

meropenem bausch health 500 mg

bausch health ireland limited , Írsko - meropeném - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)

Meropenem Bausch Health 1 000 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

meropenem bausch health 1 000 mg

bausch health ireland limited , Írsko - meropeném - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)

Ampicillin/Sulbactam Bausch Health 2 g/1 g Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ampicillin/sulbactam bausch health 2 g/1 g

bausch health ireland limited , Írsko - ampicilín a inhibítor betalaktamázy - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Európska únia - slovenčina - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrel besilát - peripheral vascular diseases; stroke; myocardial infarction - antitrombotické činidlá - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segment elevation akútnom infarkte myokardu v kombinácii s asa u medicínsky liečiť pacientov nárok na thrombolytic therapy. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. Ďalšie informácie nájdete v časti 5.